Antitumor activity and safety of tivozanib (AV-951) in a phase II randomized discontinuation trial in patients with renal cell carcinoma

Journal of Clinical Oncology

Volumn 30, Issue 14, 2012, Pages 1678-1685

  Nosov, Dmitry A ^a   Esteves, Brooke ^c   Lipatov, Oleg N ^b   Lyulko, Alexei A ^e   Anischenko, A A ^f   Chacko, Raju T ^g   Doval, Dinesh C ^h   Strahs, Andrew ^c   Slichenmyer, William J ^c   Bhargava, Pankaj ^d  

^a N N BLOKHIN RUSSIAN CANCER RESEARCH CENTER   (Russian Federation)

^b Bashkortostan Clinical Oncology Center   (Russian Federation)

^c AVEO ONCOLOGY   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e Zaporizhya Medical Academy of Postgraduate Education   (Ukraine)

^f Donetsk Regional Antitumor Center   (Ukraine)

^g CHRISTIAN MEDICAL COLLEGE   (India)

^h RAJIV GANDHI CANCER INSTITUTE AND RESEARCH CENTRE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; TIVOZANIB; CARBANILAMIDE DERIVATIVE; QUINOLINE DERIVATIVE;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; CANCER GROWTH; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPHONIA; FATIGUE; FEMALE; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; HYPOKALEMIA; KIDNEY CARCINOMA; LIVER TOXICITY; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; METASTASIS; MULTIPLE CYCLE TREATMENT; NEPHRECTOMY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STOMATITIS; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR VOLUME; CANCER INVASION; CANCER STAGING; CLINICAL TRIAL; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CROSSOVER PROCEDURE; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG TOXICITY; FOLLOW UP; KAPLAN MEIER METHOD; KIDNEY TUMOR; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MORTALITY; ORAL DRUG ADMINISTRATION; PATHOLOGY; PATIENT SAFETY; REFERENCE VALUE; RISK ASSESSMENT; SURVIVAL; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADMINISTRATION, ORAL; ADULT; AGED; CARCINOMA, RENAL CELL; CONFIDENCE INTERVALS; CROSS-OVER STUDIES; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG TOXICITY; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; KIDNEY NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PATIENT SAFETY; PHENYLUREA COMPOUNDS; QUINOLINES; REFERENCE VALUES; RISK ASSESSMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84863755452     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.35.3524     Document Type: Article

References (28)

1. Ferlay J, Shin HR, Bray F et al.: GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10. Lyon, France, International Agency for Research on Cancer, 2010. http:// globocan.iarc.fr
2. Rini BI, Campbell SC, Escudier B: Renal cell carcinoma. Lancet 373:1119-1132, 2009
3. Gnarra JR, Tory K, Weng Y, et al: Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 7:85-90, 1994
4. Rini BI: Vascular endothelial growth factor-targeted therapy in metastatic renal cell carcinoma. Cancer 115:2306-2312, 2009
5. Rini BI, Small EJ: Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J Clin Oncol 23:1028-1043, 2005
6. Escudier B, Eisen T, Stadler WM, et al: Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125-134, 2007
7. Motzer RJ, Hutson TE, Tomczak P, et al: Sunitinib versus interferon α in metastatic renal-cell carcinoma. N Engl J Med 356:115-124, 2007
8. Motzer RJ, Michaelson MD, Rosenberg J, et al: Sunitinib efficacy against advanced renal cell carcinoma. J Urol 178:1883-1887, 2007
9. Sternberg CN, Davis ID, Mardiak J, et al: Pazopanib in locally advanced or metastatic renal cell carcinoma: Results of a randomized phase III trial. J Clin Oncol 28:1061-1068, 2010
10. Escudier B, Szczylik C, Hutson TE, et al: Randomized phase II trial of first-line treatment with sorafenib versus interferon α-2a in patients with metastatic renal cell carcinoma. J Clin Oncol 27: 1280-1289, 2009
11. Escudier B, Pluzanska A, Koralewski P, et al: Bevacizumab plus interferon α-2a for treatment of metastatic renal cell carcinoma: A randomised, double-blind phase III trial. Lancet 370:2103-2111, 2007
12. Rini BI, Halabi S, Rosenberg JE, et al: Bevacizumab plus interferon α compared with interferon αmonotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 26:5422-5428, 2008
13. Rini BI, Flaherty K: Clinical effect and future considerations for molecularly-targeted therapy in renal cell carcinoma. Urol Oncol 26:543-549, 2008
14. Takahashi H, Shibuya M: The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions. Clin Sci (Lond) 109:227-241, 2005
15. Nakamura K, Taguchi E, Miura T, et al: KRN951, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, has antitumor activities and affects functional vascular properties. Cancer Res 66:9134-9142, 2006
16. Eskens FALM, De Jonge Med J Aust, Esteves B, et al: Updated results from a phase I study of AV-951 (KRN951), a potent and selective VEGFR-1, -2 and -3 tyrosine kinase inhibitor, in patients with advanced solid tumors. Presented at the 99th Annual Meeting of the American Association for Cancer Research, San Diego, CA, April 12-16, 2008 (abstr LB-2010)
17. Ratain MJ, Eisen T, Stadler WM, et al: Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 24:2505-2512, 2006
18. Hutson TE, Davis ID, Machiels JP, et al: Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma. J Clin Oncol 28:475-480, 2010
19. Rosner GL, Stadler W, Ratain MJ: Randomized discontinuation design: Application to cytostatic antineoplastic agents. J Clin Oncol 20:4478-4484, 2002
20. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
21. Kaelin Jr. WG, George DJ: The molecular biology of kidney cancer and its clinical translation into treatment strategies, in Bukowski RM (ed): Renal Cell Carcinoma: Molecular Targets and Clinical Applications. New York, NY, Humana Press, 2011, pp 79-98
22. Rini BI: Metastatic renal cell carcinoma: Many treatment options, one patient. J Clin Oncol 27: 3225-3234, 2009
23. Mir O, Ropert S, Alexandre J, et al: Hypertension as a surrogate marker for the activity of anti- VEGF agents. Ann Oncol 20:967-970, 2009
24. Schiller JH, Larson T, Ou SH, et al: Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: Results from a phase II study. J Clin Oncol 27:3836-3841, 2009
25. Rini BI, Cohen DP, Lu DR, et al: Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 103:763-773, 2011
26. Motzer RJ, Rini BI, Bukowski RM, et al: Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295:2516-2524, 2006
27. Cotreau MM, Bhargava P, Esteves B, et al: Comparison of the pharmacokinetics of tivozanib in oncology subjects compared with healthy volunteers. Clin Pharmacol Ther 89:S95-S101, 2011
28. Fishman MN, Srinivas S, Hauke RJ, et al: Combination of tivozanib (AV-951) and temsirolimus in patients with renal cell carcinoma (RCC): preliminary results from a phase 1 trial. Mol Cancer Ther 8, 2009 (suppl 12; abstr B60)